You just read:

Lilly's AWARD-11 trial studying higher investigational doses of Trulicity® (dulaglutide) demonstrated superiority in A1C reduction in people with type 2 diabetes

News provided by

Eli Lilly and Company

Jun 26, 2019, 06:45 ET